Thereof, designing targeted therapies that can enhance the levels of ROS and impede glioma proliferation via inhibition of PI3K/AKT/mTOR pathway are vitally important as they might improve glioma patient therapeutic outcome (Taylor et al., 2019). This evidence concerns the gene AKT1 and central nervous system cancer.